Heart Failure: A Global Pandemic

HF Hospitalizations
#1 Leading Cause

1 in 5 will develop HF

Patients

<table>
<thead>
<tr>
<th>Year</th>
<th>Number of Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>20 M</td>
</tr>
<tr>
<td>2030</td>
<td>40 M</td>
</tr>
</tbody>
</table>

Costs

<table>
<thead>
<tr>
<th>Year</th>
<th>Cost (B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2018</td>
<td>$100 B</td>
</tr>
<tr>
<td>2030</td>
<td>$300 B</td>
</tr>
</tbody>
</table>
Heart Failure: A Progressive and Terminal Disease

TREATMENT OPTIONS

Class 1
No Physical Limitation
Medication

Class 2
Some Physical Limitation
Stents, Rhythm Management

Class 3
Marked Physical Limitation
Therapeutic Gap

Class 4
Severe Physical Limitation
LVAD or Heart Transplant

CoRISMA Inc Target Market
Class 3 + 4
Advanced Heart Failure (AHF)
Market Research
WHAT DOES THE MARKET NEED?

3 Main Requirements Emerged

1. Blood Pump Implant (>5 liters/min)

2. Catheter Procedure (no surgery)

3. Fully Implanted / Wirelessly powered (no transdermal driveline)
Miniature Impeller Pump

- 8mm Pump Enables Catheter Delivery
- Tested Flow Rate = >6 liters / min
- Cover Article: August 2020 ASAIO Journal
- Patented Design
- Further enables transcatheter delivery
- Expands Indication:
  - Systolic AND Diastolic HF Patients
- Patented Design
Wireless Power Transmission

- Enables Fully Implanted Device
- Eliminates transdermal drivelines
- Patented Design

“All my LVAD patients would opt for another surgery to eliminate their driveline”
Leading Cardiologist, Hartford Hospital
Flushing and Maintenance System

- Enables safe positioning in bloodstream
- BiO-valve isolates pump from bloodstream
- Awarded NIH Grant ($555k SBIR Phase 1 Grant)
- Patented Design

“I believe your maintenance technology is truly unique”
Program Director, National Heart, Lung, and Blood Institute, NIH
CoRISMA Advantages

**Competition**
HeartMate 3 & Heartware

<table>
<thead>
<tr>
<th></th>
<th>Total Procedural Costs</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>$300k</td>
<td>$150k</td>
<td></td>
</tr>
<tr>
<td>10 / 20 Days</td>
<td>Hospital Stay ICU/Total</td>
<td>2 / 4 Days</td>
</tr>
<tr>
<td>10-20%</td>
<td>Stroke Rate</td>
<td>✓ 1.7%*</td>
</tr>
<tr>
<td>20%</td>
<td>Power Line Infection</td>
<td>✓ 0%</td>
</tr>
<tr>
<td>Low</td>
<td>Quality of Life</td>
<td>✓ High</td>
</tr>
</tbody>
</table>

“What you have is truly transformative”
Lead Cardiothoracic Surgeon, Stanford University School of Medicine

* Stroke rate anticipated to drop to average stroke rate of similar catheter procedures
Team: Experience, track record, and vision to succeed

Mike Theran
CEO, CoFounder

Jim Kelley
VP R&D

Colin Rolph
CFO

John Andres JD
IP Strategy

Nandini Murthy
VP Regulatory

Edward Berger
VP Reimbursement

Scott Wampler
VP Quality

Pramod Bonde MD
Chairman SAB, CoFounder

Vivek Reddy MD
Advisor

Srijoy Mahapatra MD
Advisor
Total Addressable Market without CoRISMA

- Strong Market
  - 14% CAGR Forecasted
  - >$7B

<table>
<thead>
<tr>
<th>Year</th>
<th>Market ($B)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2021</td>
<td>$1 B</td>
</tr>
<tr>
<td>2022</td>
<td>$2 B</td>
</tr>
<tr>
<td>2023</td>
<td>$3 B</td>
</tr>
<tr>
<td>2024</td>
<td>$4 B</td>
</tr>
<tr>
<td>2025</td>
<td>$5 B</td>
</tr>
<tr>
<td>2026</td>
<td>$6 B</td>
</tr>
<tr>
<td>2027</td>
<td>$7 B</td>
</tr>
<tr>
<td>2028</td>
<td>$8 B</td>
</tr>
<tr>
<td>2029</td>
<td>$9 B</td>
</tr>
<tr>
<td>2030</td>
<td>$10 B</td>
</tr>
</tbody>
</table>
Total Addressable Market with CoRISMA

“Heart Failure device market is fertile ground”
Former Chief Medical Officer Medtronic
Financial Projections

Rapid Adoption Anticipated
- Catheter procedures disrupt markets
- All Stakeholders are motivated
  - Patients
  - Clinicians
  - Hospitals
  - Insurance Companies
  - Governments
Financial Projections

Revenue Expected During Clinical
- Anticipate IDE Category B Designation*

* FDA Classification: Allow coverage of device during clinical study
<table>
<thead>
<tr>
<th></th>
<th>CoRISMA Drives Major Market Expansion</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Multiple Innovative, Patented, &amp; Disruptive Features</td>
</tr>
<tr>
<td></td>
<td>Strong and Experienced team</td>
</tr>
</tbody>
</table>

“CoRISMA has potential to be the most impactful cardiovascular device in decades”
Vivek Reddy MD, Mt Sinai Hospital New York
Contact Information

Mike Theran
Chief Executive Officer
CoRISMA Inc.
203-506-5025
www.linkedin.com/in/mike-theran
www.corismacv.com
Funding Rounds
Target Exit: Before Series C

SEED: $1.1 M (Closed)
- NIH Grant: $555k
- Finalize testing, IP & Reg Plan
- Hire VP R&D

NIH Grant: $555k
- Finalize testing, IP & Reg Plan
- Hire VP R&D

SERIES A Equity Finance: $12M
- Freeze Design
- Animal Testing

SERIES A
2020
2021
2022
2023
2024
2025
2026

SERIES B: $15M
- GLP Animal Study
- Obtain Human Study Approval

SERIES B
- GLP Animal Study
- Obtain Human Study Approval

SERIES C: $25M
- Complete Pilot Clinical Trial

SERIES C
- Complete Pilot Clinical Trial
- Receive FDA Approval

SERIES D
- Complete Pivotal Clinical Study
- Receive FDA Approval

TARGET EXIT WINDOW

2023